# IU/JAX/Pitt MODEL-AD: Deep Phenotyping Proteomics Year 1

> **NIH NIH U54** · INDIANA UNIVERSITY INDIANAPOLIS · 2020 · $410,578

## Abstract

PROJECT SUMMARY FOR FUNDED PARENT AWARD (OVERALL)
Alzheimer's disease (AD) is a major cause of dementia, disability and death in the elderly. Despite recent
advances in our understanding of basic biological mechanisms underlying AD, we do not yet know how to prevent
AD or have an approved disease modifying intervention. Both are essential to slow or stop the growth in dementia
prevalence. The National Alzheimer's Project Act (NAPA) seeks to prevent and effectively treat AD by 2025
through innovative research on etiology, early detection, and therapeutics. In support of NAPA's goals, one of
the targeted areas of research identified at the NIA sponsored 2015 Alzheimer's Disease Research Summit was
the development of the next generation of animal models of AD that will prove more predictive in preclinical
studies and thus accelerate the drug testing pipeline. While our current animal models of AD have provided
multiple novel insights into AD disease mechanisms, thus far they have not been successfully utilized to predict
the effectiveness of therapies that have moved into AD clinical trials. The Indiana University (IU)/Jackson
Laboratory (JAX) Alzheimer's Disease Precision Models Center (IU/JAX ADPMC) will leverage IU's
strengths in neurodegenerative research including 25 years as an NIA-supported Alzheimer's Disease
Center (ADC) and considerable expertise in preclinical drug testing with JAX's eight decades of expertise
in mammalian genetics and disease modeling to develop, validate and disseminate new, precise animal
models of Alzheimer's disease (AD). In addition, the IU/JAX ADMPC contains Sage Bionetworks to provide
expertise in data organization and dissemination. The IU/JAX ADPMC brings together an international,
multi-disciplinary team—including geneticists and genetics technology experts, quantitative and
computational biologists, clinical experts in AD and neuroimaging, pharmacologists and world leaders in
the development of precision animal models of disease—that possesses the collective ability to foresee
disease modeling needs as they emerge on the international stage. This will allow the IU/JAX ADPMC to
serve the AD scientific community effectively and efficiently. The IU/JAX ADPMC will generate new AD
modeling processes and pipelines, data resources, research results and models that will be swiftly shared
through JAX's and Sage's proven dissemination pipelines and through the NIA-supported AD Centers,
academic medical centers, research institutions and the pharmaceutical industry worldwide. Ultimately, this
will accelerate the application of advances in animal models for the greatest possible medical benefit. The
Specific Aims of the IU/JAX ADPMC are:
1. Maximize Human Datasets to Identify Putative Variants, Genes and Biomarkers for AD.
2. Generate and Characterize the Next Generation of Mouse Models of AD.
3. Validate the Next Generation of Mouse Models of AD and Develop a Preclinical Testing Pipeline.

## Key facts

- **NIH application ID:** 10092243
- **Project number:** 3U54AG054345-04S3
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Gregory W Carter
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $410,578
- **Award type:** 3
- **Project period:** 2016-09-30 → 2020-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10092243

## Citation

> US National Institutes of Health, RePORTER application 10092243, IU/JAX/Pitt MODEL-AD: Deep Phenotyping Proteomics Year 1 (3U54AG054345-04S3). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10092243. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*